DBV Technologies Announces Updates to Food Allergy Clinical Program at 47th Annual Conference
DBV Technologies, a biopharmaceutical company specializing in food allergies, announced modifications to its clinical development program during its presentation at the 47th annual conference of the American Academy of Allergy, Asthma & Immunology (AAAAI), according to a company press release. The updates focus on advancing its Viaskin peanut patch, a topical immunotherapy treatment, and include new data from phase 3 trials.
Company Overview and Key Focus
DBV Technologies, based in France, has been a leader in developing treatments for IgE-mediated food allergies. Its flagship product, Viaskin peanut, is designed to desensitize patients through epicutaneous immunotherapy (EPIT), a method that delivers allergens through the skin. The company’s work has been supported by clinical trials conducted in partnership with institutions such as the University of Virginia and the National Institute of Allergy and Infectious Diseases (NIAID).
Conference Presentation Highlights
At the AAAAI conference, DBV Technologies shared preliminary results from its phase 3 trial, which involved over 600 participants with peanut allergies. The data showed that 45% of patients treated with the Viaskin peanut patch achieved desensitization, defined as tolerating a 1,000-mg peanut protein dose without severe reactions. These findings were presented by Dr. Jonathan Bernstein, a clinical professor at the University of Cincinnati and a member of the company’s advisory board.
Clinical Program Adjustments
The company announced plans to refine its trial protocols to better assess long-term efficacy and safety. This includes expanding the study population to include younger children and incorporating real-world data from patient registries. “Our goal is to ensure the treatment is accessible and effective across diverse patient groups,” said DBV Technologies’ Chief Medical Officer, Dr. Sarah Lee, in a statement.
Industry Reactions and Next Steps
The updates have drawn attention from allergists and researchers, with some emphasizing the potential of EPIT as an alternative to traditional oral immunotherapy. However, experts caution that larger, longer-term studies are needed. The Food and Drug Administration (FDA) has previously granted Breakthrough Therapy designation to Viaskin peanut, which could expedite its review process.
What’s Next for DBV Technologies?
The company plans to submit its phase 3 data to the FDA in 2024, with a potential approval timeline dependent on regulatory feedback. Meanwhile, DBV Technologies is collaborating with advocacy groups like the Food Allergy Research & Education (FARE) to improve patient access.
FAQ
What is Viaskin peanut?
Viaskin peanut is a topical patch that delivers small amounts of peanut protein through the skin to desensitize patients with peanut allergies. It is part of a broader class of treatments known as epicutaneous immunotherapy (EPIT).
How effective is the treatment?
Phase 3 trials reported that 45% of participants achieved desensitization, though individual results vary. Long-term data is still being collected.
When might the treatment be available?
DBV Technologies aims to file for FDA approval in 2024, but final approval depends on regulatory reviews and additional studies.
Key Takeaways
- DBV Technologies updated its clinical program for Viaskin peanut at the AAAAI conference.
- Phase 3 trials showed 45% of patients achieved desensitization to peanut allergens.
- The company plans to expand trials to younger patients and incorporate real-world data.
- Approval by the FDA is anticipated in 2024, pending further review.